Pfizer Inc. ( PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and ...

Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...

Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines. Read more about PFE stock here.

Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...

The NHS is offering autumn Covid boosters to the most vulnerable in October. Many pharmacies also now sell the Covid jab ...

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

The mRNA vaccine, called Comirnaty, targets the KP.2 subvariant of Omicron, replacing the previous version which targeted the ...

Currently, the KP.3 and KP.3.1.1 FLiRT variants, derivatives of KP.1 and KP.2, are the most prevalent in Canada and the ...

Along with the annual flu vaccine, the new COVID-19 vaccine formulation is now widely available in Minnesota. It comes at a ...

Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently ...

Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.

Updated rapid tests are expected to be able to detect newer variants just as a new COVID variant arrives in Minnesota.